[A25-08] Amivantamab (NSCLC, first line, combination with lazertinib) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2025
Project no.:
A25-08
Commission:
Commission awarded on 22.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations; first-line treatment
- Patients < 65 years: hint of a non-quantifiable added benefit
- Patients ≥ 65 years: hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-11
| Project no. | Title | Status |
|---|---|---|
| A22-05 | Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-10 | Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-09 | Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V | Commission completed |